Senseonics Holdings Announces Major Stock Offering Agreement

Senseonics Holdings ( (SENS) ) just unveiled an announcement.

On May 15, 2025, Senseonics Holdings, Inc. announced an underwriting agreement with TD Securities and Barclays Capital to issue and sell 100,000,000 shares of common stock at $0.50 per share, with an option for underwriters to purchase an additional 15,000,000 shares. The expected net proceeds of approximately $45.4 million, or $52.45 million if the option is exercised, will fund the launch of Eversense 365, development of pipeline products, and general corporate purposes. The offering is part of a shelf registration and includes a concurrent private placement with Abbott Laboratories for up to $25 million. The closing is expected on May 19, 2025, subject to customary conditions.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Spark’s Take on SENS Stock

According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.

Senseonics Holdings shows promise with revenue growth and strategic partnerships, but is hindered by negative profitability, high debt, and valuation challenges. The earnings call provided a positive outlook, yet operational and financial risks remain significant.

To see Spark’s full report on SENS stock, click here.

More about Senseonics Holdings

Senseonics Holdings, Inc. is a medical technology company that specializes in developing and manufacturing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Their products, such as Eversense 365 and Eversense E3, feature a small sensor inserted under the skin that communicates with a smart transmitter, sending glucose data to a mobile app on the user’s smartphone.

Average Trading Volume: 5,488,603

Technical Sentiment Signal: Strong Sell

Current Market Cap: $379.1M

Find detailed analytics on SENS stock on TipRanks’ Stock Analysis page.